Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
R-Pharm
R-Pharm
Bristol-Myers Squibb
Mayo Clinic
Amgen
Massachusetts General Hospital
Sun Yat-sen University
Sun Yat-sen University
National Institutes of Health Clinical Center (CC)
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Gilead Sciences
University of Southern California
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Rakuten Medical, Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NuCana plc
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Hummingbird Bioscience
Dana-Farber Cancer Institute
Sun Yat-sen University
Sir Run Run Shaw Hospital
City of Hope Medical Center
Hospital of Stomatology, Wuhan University
GlaxoSmithKline
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Hospital of Stomatology, Wuhan University
The University of Texas Health Science Center at San Antonio
Shanghai Jiao Tong University School of Medicine
Sun Yat-sen University
Sun Yat-sen University
OncoResponse, Inc.
Beijing Tongren Hospital
Sun Yat-sen University
AIO-Studien-gGmbH
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Bristol-Myers Squibb
Groupe Oncologie Radiotherapie Tete et Cou